PR85889

LAUSANNE, Switzerland and BOSTON, Oct. 1, 2020, /PRNewswire=KYODO JBN/--

Supporting the Company's Global Expansion to Meet Growing Clinical and

Biopharma Demand for Data-Driven Medicine

- SOPHiA GENETICS enters next stage of its global expansion with oversubscribed

Series F round exceeding $110 million, led by major health-tech fund and

followed by strategic industry leader

- Company demonstrates solidity of its business model with banks joining in the

round

- Didier Hirsch, former CFO at Agilent, joins the company's Board of Directors

and will chair its Audit Committee

SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today the

closing of a $110 million financing round to enter into the next stage of its

expansion, with a focus on supporting the growing clinical and biopharma demand

for Data-Driven Medicine worldwide.

This Series F round was led by aMoon, a leading health-tech & life sciences

venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese

Hitachi Group. The company also received the trust of prime financial

institutions Credit Suisse and the Pictet group. Existing investors Swisscom

Ventures, Endeavour Vision, Generation Investment Management, Alychlo, and

Eurazeo Growth participated in the round, as well as newcomers ACE & Company

and Famille C Invest.

Having established the world's largest Data-Driven Medicine community network

through its universal and collaborative AI platform, SOPHiA GENETICS supports

healthcare professionals by translating multiple sources of complex medical

data into valuable clinical insights. The SOPHiA Platform is used by over 1'000

healthcare institutions and has analyzed 600'000 genomic profiles; up to 17'000

new profiles a month. Through continual learning and network effects, experts

worldwide are empowered to act with confidence for better patient management.

The new funding round will boost the company's penetration in both the US and

Asian markets. Proceeds will also be dedicated to increasing the platform

multimodal capabilities and its adoption by healthcare institutions worldwide.

Leveraging this momentum, SOPHiA GENETICS will be best positioned to power

biopharma's effort to optimize and accelerate the development of new targeted

therapies.

As SOPHiA enters this new phase of rapid expansion, Didier Hirsch, former CFO

at Agilent, joins the company's Board of Directors. He will also chair the

company's Audit Committee, ushering SOPHiA GENETICS toward its next important

milestones.

"The overall demand for Data-Driven Medicine is rapidly growing, and the next

step is to successfully combine multiple sources of data to better address

clinicians' needs," said Dr. Tomer Berkovitz, Partner & CFO of aMoon. "With

this shift, more complex data will be generated, and we believe that SOPHIA's

decentralized model will play a pivotal role in empowering health organizations

to offer better patient care".

Keiji Kojima, Executive Vice President and General Manager of Hitachi's Smart

Life Business Division, added: "Over the years, SOPHiA GENETICS has emerged as

a leader in Data-Driven Medicine and we look forward to supporting the company

expand its footprint in the Japanese market and beyond."

"SOPHiA has established an impressive track record of disrupting healthcare and

enabling a decentralized approach. This new funding round will further

strengthen SOPHiA's already unique offering, performance, and life-changing

impact on patients and targeted therapies," said Troy Cox, Chairman of the

Board of Directors of SOPHiA GENETICS.

"Since inception, we knew that leveraging a wide range of data modalities

powered by cutting-edge technologies was key to sustainably deliver better

outcomes to the global healthcare community," concluded Jurgi Camblong, CEO and

Founder at SOPHiA GENETICS. "Now, with this new funding round, we can embark on

the next stage of our development and take our collaborative approach further,

delivering intelligent medicine, together."

About SOPHiA GENETICS

SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to

improve health outcomes and economics worldwide. By unlocking the power of

new-generation health data for cancer and rare diseases management, the

universal SOPHiA Platform allows clinical researchers to act with precision and

confidence. The company's innovative approach enables an ever-expanding

community of over 1,000 institutions to benefit from knowledge sharing,

fostering a new era in healthcare. SOPHiA's achievement is recognized by the

MIT Technology Review's "50 Smartest Companies".

More info: SOPHiAGENETICS.COM, follow @SOPHiAGENETICS on Twitter.

Photo - https://mma.prnewswire.com/media/1294940/SOPHiA_GENETICS_Funding.jpg

US Media Contact

Weber Shandwick for SOPHiA GENETICS

Tia Di Salvo

tdisalvo@webershandwick.com

+1 (781) 520-6262

Global Media Contact

Sophie Reymond

Senior Media Relations Specialist

sreymond@sophiagenetics.com

+41 21 694 10 75

SOURCE: SOPHiA GENETICS